Alto Neuroscience Inc.(ANRO)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

ANRO $35.81
Snapshot
$35.81
52-Week Range
$3.50 – $37.48
YTD
+115.85%
IV Rank (30D)
34.43
Straddle Price
$7.28
P/C Vol Ratio
0.70
Market Cap
$1.4B
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.77%
Beta vs SPY1.00
Cost of Equity (CAPM)10.27% (VRP-adj)
WACC11.07%
Volatility Risk Premium+122.6pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-38.4%
Book / Price17.9%
Debt / Equity0.07
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$30.10 (Market Anchor value)
SMA 20 / Bollinger Mid$34.45
Bollinger Width / SMA2075.0% (drives anchor stability)
Net Debt$-0.2B
Market Cap$1B
Peers used for multiples: ABBV, CMPS, DFTX, JNJ, NBIX, NRXP, RLMD, SUPN
Model Conviction
66%
20-Day Fair Value
≈ by Oct 8, 2026
$38.46
α +7.4% rank 74%
40-Day Fair Value
≈ by Nov 6, 2026
$36.29
α +1.4% rank 57%
60-Day Fair Value
≈ by Dec 7, 2026
$38.31
α +7.0% rank 53%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 31.5× · 3 peers
Peer EV/EBITDA n/a 0% median 19.5× · 4 peers
Peer P/B $31.53 19% median 4.9× · 6 peers
Peer P/S n/a 0% median 6.8× · 5 peers
Market Anchor (SMA50) $30.10 81% stability 85% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-09-09 · updated
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNYS
Market Cap
$1.4B

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Summary
composite
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -7.00% 2
Feb -6.34% 3
Mar -7.59% 3
Apr +12.58% 3
May -12.71% 3
Jun +4.80% 3
Jul +14.47% 3
Aug +13.74% 3
Sep -1.72% 3
Oct +18.82% 2
Nov +12.40% 2
Dec +17.73% 2
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $34.45
SMA 50: $30.10
SMA 200: $22.36
Current: $35.81
EMA 12: $35.30
EMA 26: $33.39
MACD: 1.9062 | Signal: -0.1846
BULLISH
ADX (14): 46.40
STRONG TREND
+DI: 21.54
−DI: 14.22

Momentum Oscillators

RSI (14): 64.73
NEUTRAL
Stoch %K: 65.70
Stoch %D: 74.27
Williams %R: -42.17

Volume & Volatility

BB Upper: $38.90
BB Lower: $30.00
NEUTRAL
OBV: 93,984,075
Vol SMA 20: 462,469
Vol ROC: -33.09%
ATR: $1.94
True Range: $2.76
HV 20: 48.5%
HV 30: 50.2%
HV 60: 53.4%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-09-10T00:00:00 – 2026-09-08T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Earnings History
9 of 9 under expected move
Avg Expected Move
61.18%
Avg Actual Move
4.59%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-11-12 Pre-Market 9.30% 7.02% 0.75x Within
2025-02-03 Pre-Market 26.91% 0.00% 0.00x Within
2025-03-20 Pre-Market 190.91% 2.18% 0.01x Within
2025-05-14 Pre-Market 18.05% 2.37% 0.13x Within
2025-08-13 Pre-Market 227.99% 1.57% 0.01x Within
2025-11-12 Pre-Market 17.54% 5.97% 0.34x Within
2026-03-19 After-Close 22.20% 4.24% 0.19x Within
2026-05-13 Pre-Market 20.30% 7.23% 0.36x Within
2026-08-12 After-Close 17.39% 10.69% 0.61x Within
Options Activity
IV Rank (30D)
34.43
IV Rank (7D)
36.49
Avg IV
172.8%
Straddle (30D)
$7.28
Straddle (7D)
$3.98
P/C Volume
0.70
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
pts EXTREME
ATM — / Wing —
30 DTE / 10d
pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
2.33
Correlation (SPY)
23.4%
0.05
Ann. Volatility
127.7%
SPY Volatility
12.8%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 34,248,250 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

115 filers30,689,914 shares$785.29M value89.61% of float
# Filer Shares Value % of Total % of Float Period
1 Alpha Wave Global, LP 3,707,757 $97.85M 12.46% 10.83% 2026-06-30
2 Commodore Capital LP 2,723,196 $71.87M 9.15% 7.95% 2026-06-30
3 BlackRock, Inc. Custodian 2,121,009 $55.97M 7.13% 6.19% 2026-06-30
4 PERCEPTIVE ADVISORS LLC 1,609,893 $42.49M 5.41% 4.70% 2026-06-30
5 ADAGE CAPITAL PARTNERS GP, L.L.C. 1,600,000 $42.22M 5.38% 4.67% 2026-06-30
6 VANGUARD CAPITAL MANAGEMENT LLC 1,389,477 $36.67M 4.67% 4.06% 2026-06-30
7 Spruce Street Capital LP 1,353,047 $35.71M 4.55% 3.95% 2026-06-30
8 Vivo Capital, LLC 1,208,858 $31.90M 4.06% 3.53% 2026-06-30
9 FRANKLIN RESOURCES INC Custodian 1,013,307 $26.74M 3.41% 2.96% 2026-06-30
10 VANGUARD GROUP INC Custodian 1,365,847 $24.31M 3.10% 3.99% 2025-12-31
11 ARMISTICE CAPITAL, LLC 864,000 $22.80M 2.90% 2.52% 2026-06-30
12 Affinity Asset Advisors, LLC 850,000 $22.43M 2.86% 2.48% 2026-06-30
13 Vestal Point Capital, LP 785,000 $20.72M 2.64% 2.29% 2026-06-30
14 STATE STREET CORP 685,945 $18.10M 2.31% 2.00% 2026-06-30
15 GEODE CAPITAL MANAGEMENT, LLC Custodian 678,199 $17.90M 2.28% 1.98% 2026-06-30
16 72 Investment Holdings, LLC 667,778 $17.62M 2.24% 1.95% 2026-06-30
17 NORTHERN TRUST CORP Custodian 632,701 $16.70M 2.13% 1.85% 2026-06-30
18 MILLENNIUM MANAGEMENT LLC Custodian 558,320 $14.73M 1.88% 1.63% 2026-06-30
19 Point72 Asset Management, L.P. 502,950 $13.27M 1.69% 1.47% 2026-06-30
20 Integral Health Asset Management, LLC 500,000 $13.20M 1.68% 1.46% 2026-06-30
21 Venrock Adviser, LLC 500,000 $13.20M 1.68% 1.46% 2026-06-30
22 DRIEHAUS CAPITAL MANAGEMENT LLC 487,576 $12.87M 1.64% 1.42% 2026-06-30
23 Parkman Healthcare Partners LLC 429,035 $11.32M 1.44% 1.25% 2026-06-30
24 Ikarian Capital, LLC 407,338 $10.75M 1.37% 1.19% 2026-06-30
25 ORBIMED ADVISORS LLC 257,852 $6.80M 0.87% 0.75% 2026-06-30
3 filers$1.90M notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $881.43K 46.32% 2026-06-30
2 JANE STREET GROUP, LLC Custodian $622.80K 32.73% 2026-06-30
3 CITADEL ADVISORS LLC Custodian $398.49K 20.94% 2026-06-30
1 filers$736.28K notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $736.28K 100.00% 2026-06-30
Insider Activity
Latest: 2026-05-29
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-05-29 Andrew Craig Miller Director Grant (A) +26,000 opt EDGAR
2026-05-15 Amit Etkin PRESIDENT AND CEO Gift (G) −400,000 EDGAR
2026-05-14 Andrew Dreyfus Director Grant (A) +10,958 opt EDGAR
2026-05-14 Husseini Manji Director Grant (A) +10,958 opt EDGAR
2026-05-14 Ramiro Sanchez Director Grant (A) +10,958 opt EDGAR
2026-05-14 Gwill York Director Grant (A) +10,958 opt EDGAR
2026-05-14 Christopher Nixon Cox Director Grant (A) +10,958 opt EDGAR
2026-03-03 Amit Etkin PRESIDENT AND CEO Tax (F) −6,227 $19.69 -$122.6K EDGAR
2026-03-03 Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO Tax (F) −2,806 $19.69 -$55.3K EDGAR
2026-02-13 Jr. Michael Conick Hanley CHIEF OPERATING OFFICER Grant (A) +131,000 opt EDGAR
2026-02-13 Adam Savitz CHIEF MEDICAL OFFICER Grant (A) +124,000 opt EDGAR
2026-02-13 Amit Etkin PRESIDENT AND CEO Grant (A) +306,000 opt EDGAR
2026-02-13 Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO Grant (A) +200,000 opt EDGAR
2026-01-06 Christopher Nixon Cox Director Grant (A) +7,189 opt EDGAR
2026-01-06 Ramiro Sanchez Director Grant (A) +3,806 opt EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
8 insiders · @ $35.81
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Chimera Investment LLC 10%+ Owner 1,962,995 $70.29M $38.40M 1 2024-02-08
2 Apeiron Investment Group Ltd. 926,539 $33.18M $0 1 2024-03-06
3 Amit Etkin PRESIDENT AND CEO 833,949 $29.86M $50.0K 7 2026-05-15
4 Christopher Nixon Cox Director 588,898 $21.09M $0 6 2026-05-14
5 Po Yu (Jeff) Chen Director 39,259 $1.41M $0 2 2024-02-07
6 Adam Savitz CHIEF MEDICAL OFFICER 36,920 $1.32M $462.8K 6 2026-02-13
7 Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO 24,060 $861.6K $125.6K 7 2026-03-03
8 Gwill York Director 23,917 $856.5K $0 6 2026-05-14
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio6.4
EV/EBITDA-13.4
TTM Net Income$-0.1B
TTM EPS$-2.42
ROE-38.4%
Debt/Equity0.09